CNA Database
Jump to navigation
Jump to search
Disease Name | MESH header | Disease Id | Prognosis | Gene Name | Band | Cytogenetic Aberration | Non-cytogenetic Characteristic | Gene Entrez ID | Cytoband | Aberration | Aberration Label | Described Effect | Bearing | Therapy Type | Therapy Name | Therapy Class | Therapy Id | Diagnostic, Prognostic, Therapy related | pubmed ids |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Non Small Cell Lung Cancer | Carcinoma, Non-Small-Cell Lung | D002289 | MET | 7q31.2 | Amplification | 4233 | 7q31.2 | Gain | MET Amplification | Targeted Therapies May Be Available (i.e. Crizotinib) | pos | drug | Crizotinib | Therapy | PMID 21716144 PMID 26628860 | ||||
Gastrointestinal Stromal Tumors | Gastrointestinal Stromal Tumors | D046152 | KIT | 4q12 | Amplification | 3815 | 4q12 | Gain | KIT Amplification | Targeted Therapies May Be Available (i.e. Tyrosine Kinase Inhibitors); Recurring in Gastrointestinal Stromal Tumor; Imatinib Mylate Treatment | pos | drug | Imatinib Mesylate | Therapy | 26098203 | ||||
Non Small Cell Lung Cancer | Carcinoma, Non-Small-Cell Lung | D002289 | CRKL | 22q11.21 | Amplification | 1399 | 22q11.21 | Gain | CRKL Amplification | Associated With EGFR-TKI Resistance | neg | drug | EGFR tyrosine kinase inhibitor | Therapy | 24939008, 22586683 | ||||
Non Small Cell Lung Cancer | Carcinoma, Non-Small-Cell Lung | D002289 | MET | 7q31.2 | Amplification | 4233 | 7q31.2 | Gain | MET Amplification | Acquired Resistance To EGFR Inhibitors In EGFR-Mutant Tumors | neg | drug | EGFR inhibitors | Therapy | 24348666, 26628860 | ||||
Non Small Cell Lung Cancer | Carcinoma, Non-Small-Cell Lung | D002289 | FGFR1 | 8p11.22 | Amplification | 2260 | 8p11.22 | Gain | FGFR1 Amplification | Inhibited By Ponatinib Treatment | pos | drug | Ponatinib | Therapy | 23563700 | ||||
Squamous Cell Lung Cancer | Lung Neoplasms | D008175 | MYC | 8q24.21 | Overexpression | 4609 | 8q24.21 | Gain | MYC overexpression | Benefit From FGFR Inhibitor Therapy With Concomitant FGFR1 Amplification | pos | drug | FGFR inhibitor | Therapy | 24302556 | ||||
Squamous Cell Lung Cancer | Lung Neoplasms | D008175 | FGFR1 | 8p11.22 | 8p11.22 Amplification | Amplification | 2260 | 8p11.22 | Gain | FGFR1 Amplification | Benefit From FGFR Inhibitor Therapy With Concomitant MYC Overexpression | pos | drug | FGFR inhibitor | Therapy | 24302556 | |||
Ovarian | Ovarian Neoplasms | D010051 | CCNE1 | 19q12 | Amplification | 898 | 19q12 | Gain | CCNE1 Amplification | Targeted Therapies May Be Available (i.e. CDK2 Inhibitors) | pos | CDK2 inhibitor | Therapy | 23289505, 26204491, 25633797, 25892415 | |||||
Ovarian | Ovarian Neoplasms | D010051 | ERBB2 | 17q12 | Amplification | 2064 | 17q12 | Gain | HER2 Amplification | Targeted Therapies May Be Available (i.e. HER2 Inhibitors) | pos | HER2 inhibitor | Therapy | 25674538 | |||||
Ovarian | Ovarian Neoplasms | D010051 | KRAS | 12p12.1 | Amplification | 3845 | 12p12.1 | Gain | KRAS Amplification | Targeted Therapies May Be Available (i.e. RAS Inhibitors) | pos | RAS inhibitor | Therapy | 23289505, 26691679 | |||||
Ovarian | Ovarian Neoplasms | D010051 | BRCA1 | 17q21.31 | Deletion | 672 | 17q21.31 | Loss | BRCA1 Deletion | Targeted Therapies May Be Available (i.e.PARP Inhibitors) | pos | PARP inhibitors | Therapy | 24225019, 26483957 | |||||
Ovarian | Ovarian Neoplasms | D010051 | BRCA2 | 13q13.1 | Deletion | 675 | 13q13.1 | Loss | BRCA2 Deletion | Targeted Therapies May Be Available (i.e. PARP Inhibitors) | pos | PARP inhibitors | Therapy | 24225019, 26483957 | |||||
Ovarian | Ovarian Neoplasms | D010051 | PTEN | 10q23.31 | Bi-allelic deletion | 5728 | 10q23.31 | Loss | PTEN Bi-allelic deletion | Targeted Therapies May Be Available (i.e. PI3K Pathway Inhibitors) | pos | PI3K pathway inhibitors | Therapy | 24387334, 23289505, 25533673 | |||||
Myelodysplastic Syndrome | Myelodysplastic Syndromes | D009190 | 5q deletion | 5q | Loss | 5q deletion | Targeted Therapies May Be Available (i.e. Lenalidomide) | pos | drug | Lenalidomide | Therapy | 22488943 | |||||||
Diffuse Large B-Cell Lymphoma | Lymphoma, Large B-Cell, Diffuse | D016403 | 1p36.13 amplification | 1p36.13 | Gain | 1p36.13 amplification | Associated With Chemoresistance | neg | chemotherapy | Chemotherapy | Therapy | 21504712 | |||||||
Diffuse Large B-Cell Lymphoma | Lymphoma, Large B-Cell, Diffuse | D016403 | 1p42.3 amplification | 1p42.3 | Gain | 1p42.3 amplification | Associated With Chemoresistance | neg | chemotherapy | Chemotherapy | Therapy | 21504712 | |||||||
Diffuse Large B-Cell Lymphoma | Lymphoma, Large B-Cell, Diffuse | D016403 | 3p21.31 amplification | 3p21.31 | Gain | 3p21.31 amplification | Associated With Chemoresistance | neg | chemotherapy | Chemotherapy | Therapy | 21504712 | |||||||
Diffuse Large B-Cell Lymphoma | Lymphoma, Large B-Cell, Diffuse | D016403 | 7q11.23 amplification | 7q11.23 | Gain | 7q11.23 amplification | Associated With Chemoresistance | neg | chemotherapy | Chemotherapy | Therapy | 21504712 | |||||||
Diffuse Large B-Cell Lymphoma | Lymphoma, Large B-Cell, Diffuse | D016403 | 16p13.3 amplification | 16p13.3 | Gain | 16p13.3 amplification | Associated With Chemoresistance | neg | chemotherapy | Chemotherapy | Therapy | 21504712 | |||||||
Diffuse Large B-Cell Lymphoma | Lymphoma, Large B-Cell, Diffuse | D016403 | 9p21.3 loss | 9p21.3 | Loss | 9p21.3 loss | Associated With Chemoresistance | neg | chemotherapy | Chemotherapy | Therapy | 21504712 | |||||||
Diffuse Large B-Cell Lymphoma | Lymphoma, Large B-Cell, Diffuse | D016403 | 14q11.2 loss | 14q11.2 loss | Loss | 14q11.2 loss | Associated With Chemoresistance | neg | chemotherapy | Chemotherapy | Therapy | 21504712 | |||||||
Diffuse Large B-Cell Lymphoma | Lymphoma, Large B-Cell, Diffuse | D016403 | CDKN2A | 9p21.3 | Loss | 1029 | 9p21.3 | Loss | CDKN2A/B Loss | Associated With Chemoresistance | neg | chemotherapy | Chemotherapy | Therapy | 21504712 | ||||
Diffuse Large B-Cell Lymphoma | Lymphoma, Large B-Cell, Diffuse | D016403 | CDKN2B | 9p21.3 | Loss | 1030 | 9p21.3 | Loss | CDKN2A/B Loss | Associated With Chemoresistance | neg | chemotherapy | Chemotherapy | Therapy | 21504712 | ||||
Diffuse Large B-Cell Lymphoma | Lymphoma, Large B-Cell, Diffuse | D016403 | 1p36.11 gain | 1p36.11 | Gain | 1p36.11 gain | Associated With Chemo-Sensitive | pos | chemotherapy | Chemotherapy | Therapy | 21504712 | |||||||
Diffuse Large B-Cell Lymphoma | Lymphoma, Large B-Cell, Diffuse | D016403 | 1p36.22 gain | 1p36.22 | Gain | 1p36.22 gain | Associated With Chemo-Sensitive | pos | chemotherapy | Chemotherapy | Therapy | 21504712 | |||||||
Diffuse Large B-Cell Lymphoma | Lymphoma, Large B-Cell, Diffuse | D016403 | 2q11.2 gain | 2q11.2 | Gain | 2q11.2 gain | Associated With Chemo-Sensitive | pos | chemotherapy | Chemotherapy | Therapy | 21504712 | |||||||
Diffuse Large B-Cell Lymphoma | Lymphoma, Large B-Cell, Diffuse | D016403 | 8q24.3 gain | 8q24.3 | Gain | 8q24.3 gain | Associated With Chemo-Sensitive | pos | chemotherapy | Chemotherapy | Therapy | 21504712 | |||||||
Diffuse Large B-Cell Lymphoma | Lymphoma, Large B-Cell, Diffuse | D016403 | 12p13.33 gain | 12p13.33 | Gain | 12p13.33 gain | Associated With Chemo-Sensitive | pos | chemotherapy | Chemotherapy | Therapy | 21504712 | |||||||
Diffuse Large B-Cell Lymphoma | Lymphoma, Large B-Cell, Diffuse | D016403 | 22q13.2 gain | 22q13.2 | Gain | 22q13.2 gain | Associated With Chemo-Sensitive | pos | chemotherapy | Chemotherapy | Therapy | 21504712 | |||||||
Diffuse Large B-Cell Lymphoma | Lymphoma, Large B-Cell, Diffuse | D016403 | 6p21.32 loss | 6p21.32 | Loss | 6p21.32 loss | Associated With Chemo-Sensitive | pos | chemotherapy | Chemotherapy | Therapy | 21504712 | |||||||
Mantle Cell Lymphoma | Lymphoma, Mantle-Cell | D020522 | MDM2 | 12q15 | Amplification | 4193 | 12q15 | Gain | MDM2 Amplification | Target For Nutlin-3 Therapy (MDM2 Antagonist; Activate TP53) | pos | drug | Nutlin-3 | Therapy | 23303139, 25439588, 25201201 | ||||
Breast Cancer | Breast Neoplasms | D001943 | ERBB2 | 17q12 | Amplification | Increased expression | 2064 | 17q12 | Gain | ERBB2 Amplification | Targeted Therapies May Be Available (i.e. ERBB2 Inhibitor (HER2)) | pos | drug | ERBB2 inhibitor (HER2) | Therapy | 24470511, 24921704, 25674538, 26557900, 26635612 | |||
Renal Cell Carcinoma | Carcinoma, Renal Cell | D002292 | KIT | 4q12 | Amplification | Increased expression | 3815 | 4q12 | Gain | KIT Amplification | Targeted Therapies May Be Available (i.e. KIT Inhibitor) | pos | drug | KIT inhibitor | Therapy | 24190702 | |||
Renal Cell Carcinoma | Carcinoma, Renal Cell | D002292 | PDGFRB | 5q32 | Amplification | Increased expression | 5159 | 5q32 | Gain | PDGFRB Amplification | Targeted Therapies May Be Available (i.e. PDGFRB Inhibitor) | pos | drug | PDGFRB inhibitor | Therapy | 24359404, 24872713 | |||
Renal Cell Carcinoma | Carcinoma, Renal Cell | D002292 | FLT1 | 13q12.3 | Amplification | Increased expression | 13q12.3 | Gain | VEGFR Amplification | Targeted Therapies May Be Available (i.e. VEGFR 1/2/3 Inhibitor) | pos | drug | VEGFR 1/2/3 inhibitor | Therapy | 24243495, 25482937, 25773809 | ||||
Renal Cell Carcinoma | Carcinoma, Renal Cell | D002292 | KDR | 4q12 | Amplification | Increased expression | 4q12 | Gain | VEGFR Amplification | Targeted Therapies May Be Available (i.e. VEGFR 1/2/3 Inhibitor) | pos | drug | VEGFR 1/2/3 inhibitor | Therapy | 24243495, 26309897 | ||||
Renal Cell Carcinoma | Carcinoma, Renal Cell | D002292 | FLT4 | 5q35.3 | Amplification | Increased expression | 5q35.3 | Gain | VEGFR Amplification | Targeted Therapies May Be Available (i.e. VEGFR 1/2/3 Inhibitor) | pos | drug | VEGFR 1/2/3 inhibitor | Therapy | 24243495 | ||||
Colorectal Cancer | Colorectal Neoplasms | D015179 | VEGFA | 6p21.1 | Amplification | Increased expression | 6p21.1 | Gain | VEGF Amplification | Targeted Therapies May Be Available (i.e. VEGF Inhibitor) | pos | drug | VEGF inhibitor | Therapy | 24355210 | ||||
Colorectal Cancer | Colorectal Neoplasms | D015179 | VEGFB | 11q13.1 | Amplification | Increased expression | 11q13.1 | Gain | VEGF Amplification | Targeted Therapies May Be Available (i.e. VEGF Inhibitor) | pos | drug | VEGF inhibitor | Therapy | 24355210 | ||||
Glioblastoma | Glioblastoma | D005909 | VEGFA | 6p21.1 | Amplification | Increased expression | 6p21.1 | Gain | VEGF Amplification | Targeted Therapies May Be Available (i.e. VEGF Inhibitor) | pos | drug | VEGF inhibitor | Therapy | 24076268 | ||||
Glioblastoma | Glioblastoma | D005909 | VEGFB | 11q13.1 | Amplification | Increased expression | 11q13.1 | Gain | VEGF Amplification | Targeted Therapies May Be Available (i.e. VEGF Inhibitor) | pos | drug | VEGF inhibitor | Therapy | 24076268 | ||||
Non Small Cell Lung Cancer | Carcinoma, Non-Small-Cell Lung | D002289 | VEGFA | 6p21.1 | Amplification | Increased expression | 6p21.1 | Gain | VEGF Amplification | Targeted Therapies May Be Available (i.e. VEGF Inhibitor) | pos | drug | VEGF inhibitor | Therapy | 24076268 | ||||
Non Small Cell Lung Cancer | Carcinoma, Non-Small-Cell Lung | D002289 | VEGFB | 11q13.1 | Amplification | Increased expression | 11q13.1 | Gain | VEGF Amplification | Targeted Therapies May Be Available (i.e. VEGF Inhibitor) | pos | drug | VEGF inhibitor | Therapy | 24076268 | ||||
Renal Cell Carcinoma | Carcinoma, Renal Cell | D002292 | VEGFA | 6p21.1 | Amplification | Increased expression | 6p21.1 | Gain | VEGF Amplification | Targeted Therapies May Be Available (i.e. VEGF Inhibitor) | pos | drug | VEGF inhibitor | Therapy | 24243495 | ||||
Renal Cell Carcinoma | Carcinoma, Renal Cell | D002292 | VEGFB | 11q13.1 | Amplification | Increased expression | 11q13.1 | Gain | VEGF Amplification | Targeted Therapies May Be Available (i.e. VEGF Inhibitor) | pos | drug | VEGF inhibitor | Therapy | 24243495 | ||||
Medullary Thyroid Cancer | Thyroid Neoplasms | D013964 | FLT3 | 13q12.2 | Amplification | Increased expression | 2322 | 13q12.2 | Gain | FLT3 Amplification | Targeted Therapies May Be Available (i.e. FLT3 Inhibitor) | pos | drug | FLT3 inhibitor | Therapy | 24756790, 26635725 | |||
Medullary Thyroid Cancer | Thyroid Neoplasms | D013964 | KIT | 4q12 | Amplification | Increased expression | 3815 | 4q12 | Gain | KIT Amplification | Targeted Therapies May Be Available (i.e. KIT Inhibitor) | pos | drug | KIT inhibitor | Therapy | 26635725 | |||
Medullary Thyroid Cancer | Thyroid Neoplasms | D013964 | MET | 7q31.2 | Amplification | Increased expression | 4233 | 7q31.2 | Gain | MET Amplification | Targeted Therapies May Be Available (i.e. MET Inhibitor) | pos | drug | MET inhibitor | Therapy | 24266843, 26628860, 26635725 | |||
Medullary Thyroid Cancer | Thyroid Neoplasms | D013964 | RET | 10q11.21 | Amplification | Increased expression | 5979 | 10q11.21 | Gain | RET Amplification | Targeted Therapies May Be Available (i.e. RET Inhibitor) | pos | drug | RET inhibitor | Therapy | 26635725 | |||
Medullary Thyroid Cancer | Thyroid Neoplasms | D013964 | FLT1 | 13q12.3 | Amplification | Increased expression | 13q12.3 | Gain | VEGFR Amplification | Targeted Therapies May Be Available (i.e. VEGFR Inhibitor) | pos | drug | VEGFR inhibitor | Therapy | 25482937, 25773809, 26635725 | ||||
Medullary Thyroid Cancer | Thyroid Neoplasms | D013964 | KDR | 4q12 | Amplification | Increased expression | 4q12 | Gain | VEGFR Amplification | Targeted Therapies May Be Available (i.e. VEGFR Inhibitor) | pos | drug | VEGFR inhibitor | Therapy | 25773809, 26635725 | ||||
Medullary Thyroid Cancer | Thyroid Neoplasms | D013964 | FLT4 | 5q35.3 | Amplification | Increased expression | 5q35.3 | Gain | VEGFR Amplification | Targeted Therapies May Be Available (i.e. VEGFR Inhibitor) | pos | drug | VEGFR inhibitor | Therapy | 26635725 | ||||
Colorectal Cancer | Colorectal Neoplasms | D015179 | EGFR | 7p11.2 | Amplification | Increased expression | 1956 | 7p11.2 | Gain | EGFR Amplification | Targeted Therapies May Be Available (i.e. EGFR Inhibitor) | pos | drug | EGFR inhibitor | Therapy | 24472471, 25110867 | |||
Squamous Cell Cancer Of Head And Neck | Head and Neck Neoplasms | D006258 | EGFR | 7p11.2 | Amplification | Increased expression | 1956 | 7p11.2 | Gain | EGFR Amplification | Targeted Therapies May Be Available (i.e. EGFR Inhibitor) | pos | drug | EGFR inhibitor | Therapy | 24412287, 25110867 | |||
Non Small Cell Lung Cancer | Carcinoma, Non-Small-Cell Lung | D002289 | ALK | 2p23.1 | Amplification | Increased expression | 238 | 2p23.1 | Gain | ALK Amplification | Targeted Therapies May Be Available (i.e. ALK Inhibitor) | pos | drug | ALK inhibitor | Therapy | 26468446, 25806340 | |||
Non Small Cell Lung Cancer | Carcinoma, Non-Small-Cell Lung | D002289 | MET | 7q31.2 | Amplification | Increased expression | 4233 | 7q31.2 | Gain | MET Amplification | Targeted Therapies May Be Available (i.e. MET Inhibitor) | pos | drug | MET inhibitor | Therapy | 24355409, 25992382 | |||
Pancreatic Cancer | Pancreatic Neoplasms | D010190 | EGFR | 7p11.2 | Amplification | Increased expression | 1956 | 7p11.2 | Gain | EGFR Amplification | Targeted Therapies May Be Available (i.e. EGFR Inhibitor) | pos | drug | EGFR inhibitor | Therapy | 24432033, 25110867 | |||
Pancreatic Neuroendocrine Tumor | Pancreatic Neoplasms | D010190 | MTOR | 1p36.22 | Amplification | Increased expression | 2475 | 1p36.22 | Gain | mTOR Amplification | Targeted Therapies May Be Available (i.e. mTOR Inhibitor) | pos | drug | mTOR inhibitor | Therapy | 24333502 | |||
Renal Cell Carcinoma | Carcinoma, Renal Cell | D002292 | MTOR | 1p36.22 | Amplification | Increased expression | 2475 | 1p36.22 | Gain | mTOR Amplification | Targeted Therapies May Be Available (i.e. mTOR Inhibitor) | pos | drug | mTOR inhibitor | Therapy | 26309897, 24333502 | |||
Gastrointestinal Stromal Tumors | Gastrointestinal Stromal Tumors | D046152 | KIT | 4q12 | Amplification | Increased expression | 3815 | 4q12 | Gain | KIT Amplification | Targeted Therapies May Be Available (i.e. KIT Inhibitor) | pos | drug | KIT inhibitor | Therapy | 24384849 | |||
Dermatofibrosarcoma Protuberans | Dermatofibrosarcoma | D018223 | PDGFRA | 4q12 | Amplification | Increased expression | 4q12 | Gain | PDGFR Amplification | Targeted Therapies May Be Available (i.e. PDGFR Inhibitor) | pos | drug | PDGFR inhibitor | Therapy | 24359404, 24872713 | ||||
Dermatofibrosarcoma Protuberans | Dermatofibrosarcoma | D018223 | PDGFRB | 5q32 | Amplification | Increased expression | 5q32 | Gain | PDGFR Amplification | Targeted Therapies May Be Available (i.e. PDGFR Inhibitor) | pos | drug | PDGFR inhibitor | Therapy | 24359404, 24872713 |